Core Viewpoint - As of July 15, 2023, AAPG's stock price increased by 2.27% to $37.02 per share, with a total market capitalization of $3.23 billion. The company reported a total revenue of 981 million RMB for the year ending December 31, 2024, representing a year-on-year growth of 341.77%, while the net profit attributable to shareholders was -405 million RMB, showing a growth of 56.2% year-on-year [1][3]. Company Overview - AAPG is a biopharmaceutical company based in China, focusing on developing innovative drugs for cancer, hepatitis B, and age-related diseases. The company was listed on the Hong Kong Stock Exchange on October 28, 2019, under the stock code 6855.HK [2]. - The company has developed a proprietary drug design platform targeting protein-protein interactions and is at the forefront of new drug development in the apoptosis pathway. AAPG has established a pipeline of nine Class 1 small molecule new drugs in clinical development, including inhibitors targeting key proteins in the apoptosis pathway [2]. - AAPG is conducting over 40 clinical trials across China, the United States, Australia, and Europe. Its core product, Orebate (brand name: Nairike), has received priority review and breakthrough therapy designation from the China National Medical Products Administration (NMPA) and has been approved for sale in China [2]. Regulatory and Collaborative Achievements - The product Nairike has been included in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2022) in China. It has also received fast track designation, orphan drug designation from the FDA, and orphan drug designation from the EU [2]. - AAPG has four investigational new drugs that have received 16 FDA orphan drug designations, two FDA fast track designations, and two FDA designations for pediatric rare diseases [2]. - The company has undertaken several national science and technology major projects, including five projects under the "Major New Drug Creation" initiative and one project for "Enterprise Innovative Drug Incubation Base" [2]. Research and Development Capabilities - AAPG has established a strong international talent team with extensive experience in original drug research and clinical development. The company is also building a high-standard commercialization and marketing team [2]. - The company aims to enhance its R&D capabilities and accelerate the clinical development of its product pipeline to meet unmet clinical needs for patients in China and globally [2].
亚盛医药上涨2.27%，报37.02美元/股，总市值32.30亿美元